Previous Article | Next Article ![]()
Journal of Clinical Microbiology, May 2004, p. 2101-2107, Vol. 42, No. 5
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.5.2101-2107.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Department of Medical Microbiology and PHLS, University Hospital of Wales,1 Department of Oral Surgery, Medicine and Pathology, University of Wales College of Medicine, Cardiff, United Kingdom2
Received 24 September 2003/ Returned for modification 15 October 2003/ Accepted 26 November 2003
|
|
|---|
|
|
|---|
70 to 75% of isolates), followed by C. glabrata and C. tropicalis (7% of isolates) (9, 13). The reported rate of oral carriage of Candida yeasts among healthy individuals has been variable but ranges from 35 to 80% (1, 4) and is dependent on the population studied and the sampling methods used. Debilitation of an individual can result in the occurrence of clinical oral candidosis, which may be defined as acute or chronic pseudomembranous candidosis (oral thrush), acute erythematous candidosis (Candida-associated denture stomatitis), chronic erythematous candidosis, or chronic hyperplastic candidosis (CHC) (3). Previously, host factors that were implicated in the onset of these infections received greater attention than the virulence factors of Candida. This was reflected in many diagnostic microbiological laboratories, where the ability to identify yeast isolates was limited. In recent years there has been increased interest in oral candidosis, partly due to the escalation of human immunodeficiency virus infection and AIDS and the more widespread use of immunosuppressive chemotherapy. As a consequence, there has been an associated increased demand for reliable sampling and identification methods.
Methods for sampling of the mouth for Candida include the taking of a smear (16), swab (15), or imprint specimen for culture (2); culture of whole saliva (24); and concentrated oral rinse culture (CRC) (10, 15). CRC is widely used, and although it does not directly target specific mucosal lesions, it provides a measure of the candidal load and can permit detection of other microbes. Candida levels of 600 CFU/ml of CRC specimen have been reported for healthy commensal carriage (10, 11), with higher numbers (
2 x 103 to 3 x 103 CFU/ml) evident in individuals with conditions that predispose them to infection (15). Samaranayake et al. (15) compared CRC with imprint culture for detection of oral microbes and found that CRC was superior for yeast detection. They subsequently recommended the use of CRC as the screening approach for detecting oral yeast carriage.
One drawback of detection methods based on culture is the delay before a diagnostic report can be made available to the clinicians. Primary isolation media are routinely incubated for 48 h at 37°C, followed by a possible 72-h incubation for physiological or biochemical identification (20). The advent of differential primary agars, such as CHROMagar Candida (CHROMagar Ltd., Paris, France) and Albicans ID (BioMérieux, Basingstoke, United Kingdom), has enabled the presumptive identification of certain species (14), although physiological identification is still recommended and is a necessity for the majority of species. More recently, the introduction of molecular PCR-based techniques has resulted in the development of tests that can potentially detect Candida directly in oral samples. One such approach, namely, real-time PCR with the LightCycler instrument (Idaho Technologies, Idaho Falls), was recently developed for the sensitive (1 to 5 CFU/ml) and rapid (1-day) detection of seven clinically relevant Candida species in blood (18).
The aim of the present study was to assess the performance of this real-time PCR for the detection of Candida species directly in CRC samples. Originally, the real-time assay was developed to detect candidemia, and so it was necessary to determine the detection limit of the real-time PCR for Candida in spiked CRC samples rather than blood. It was also essential to establish how effective the real-time assay was for detection of clinical and commensal populations by direct comparisons to the "gold standard" culture and other molecular approaches.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Agreement between culture and PCR for detection of Candida in CRC samplesa
|
|
View this table: [in a new window] |
TABLE 2. Detection of 10 Candida species in CRC samples by PCR
|
|
View this table: [in a new window] |
TABLE 3. Primers and conditions of specific PCRs used in the study
|
![]() View larger version (37K): [in a new window] |
FIG. 1. Real-time PCR melting curve showing a positive sample (top) and a negative sample (bottom). The first peak indicates probe melting, and the second peak indicates amplicon melting.
|
|
|
|---|
![]() View larger version (87K): [in a new window] |
FIG. 2. Products obtained by N18-specific PCR for diluted suspensions with 100 to 106 C. albicans (a) and C. dubiniensis (b) yeasts/ml.
|
Candida was detected by culture in 85 (59%) of the 145 clinical CRC samples and in 17 (38%) of the 48 healthy control CRC samples. Of the 85 clinical CRC samples that were culture positive, C. albicans was evident in 72 (85%). Other yeasts detected by culture, either in combination with C. albicans or alone, were C. glabrata (n = 4), C. krusei (n = 2), Candida inconspicua (n = 1), Candida spp. (n = 15), and Saccharomyces cerevisiae (n = 1). More than one Candida species was detected in 10 of the 85 samples positive by culture. C. albicans was the only species detected by culture in the 17 positive healthy control CRC samples.
Real-time PCR demonstrated that 97 (67%) of the 145 clinical CRC samples and 19 (40%) of the 48 healthy control CRC samples were positive for Candida. The N18-specific block-based PCR was positive for 109 (75%) clinical CRC samples and 22 (46%) of the healthy control CRC samples. In comparison, the ITS-specific PCR gave positive results for 93 (64%) clinical CRC samples and 25 (52%) healthy control CRC samples.
Table 1 and Fig. 3 present the agreement between Candida culture and PCR detection of Candida in the CRC samples. By using culture as the gold standard, the overall sensitivity and specificity of the real-time PCR were 94 and 78%, respectively, with only six culture-positive clinical CRC samples being negative by the real-time PCR. All six were culture negative for C. albicans. All culture-positive healthy control CRC samples were positive by real-time PCR.
![]() View larger version (31K): [in a new window] |
FIG. 3. Percent agreement of PCR and culture.
|
Among the 91 culture-negative CRC samples, the real-time PCR revealed that 20 were positive; this compares with 41 and 44 positive samples by the N18- and ITS-specific PCRs, respectively. Thirty-two culture-negative CRC samples were negative by all three PCRs. All three PCRs were positive for eight culture-negative CRC samples, and a further 30 culture-negative CRC samples were positive by two of the three PCRs (Fig. 4).
![]() View larger version (26K): [in a new window] |
FIG. 4. Agreement between negative culture and PCR results.
|
|
|
|---|
Initial studies with spiked CRC samples indicated a real-time PCR detection sensitivity of 1 to 10 yeasts/ml for C. albicans, C. parapsilosis, C. tropicalis, and C. viswanathii. The detection levels were lower for other Candida species (C. dubliniensis, C. glabrata, C. kefyr, and C. inconspicua). The Candida-specific probe did not hybridize to amplicons from C. guilliermondii or C. famata, a finding that was in agreement with our previous assessment of the PCR with blood samples (18). The Candida-specific probe had originally been designed for the detection of Candida in patients with candidemia, a condition that is primarily attributed to C. albicans and, to a lesser extent, C. tropicalis, C. parapsilosis, C. glabrata, and C. krusei (18). Modification of the probe to enable detection of C. guilliermondii and C. famata is possible, although the significance of these two species in oral candidosis remains uncertain. Having established that the real-time PCR methodology was applicable to these spiked control oral samples, the performance of the PCR was determined with 193 CRC samples. Forty-eight of these CRC samples were from individuals considered free of oral candidosis. These samples were included to ensure that an increased sensitivity of detection by real-time PCR would not result in the production of large numbers of false-positive (clinically insignificant) results. This situation would have negated the value of the PCR as a suitable clinical test; however, the results show that the real-time PCR and the gold standard culture produced comparable results for our healthy population.
Culture of the 145 clinical CRC samples from patients with a variety of oral signs and symptoms revealed that 85 were positive for Candida, representing a colonization rate of 59%. This value was noticeably higher than the 35% carriage rate for the 48 CRC samples from healthy mouths (17 positive samples), which compares favorably with the 36.8% rate published by Abu-Elteen and Abu-Alteen (1). In the case of candidal presence from patients with various disease states, the higher incidence observed was expected, although comparison with other studies is problematic due to the diversity of patient groups. The overall incidence of C. albicans in the 102 culture-positive CRC samples was 87%. This high incidence of C. albicans relative to those of the other species concurs with most studies of the candidal epidemiology of the mouth (6, 8). An interesting observation from the culture data was the apparent high incidence (compared with that in the healthy mouths) of Candida in oral conditions not primarily associated with the yeasts. This observation was particularly evident for patients with lichen planus, burning mouth syndrome, and dry mouth. The significance of Candida in these cases is uncertain, but the altered oral state in these patients may, in part, offer an environment more favorable to candidal colonization. Similar high incidences of Candida from the mouths of individuals with leukoplakia (82%), lichen planus (47%), and burning mouth syndrome have been reported (6, 7).
Overall, the real-time PCR compared favorably with culture, with the results of the real-time PCR achieving 94% agreement with those of culture for the culture-positive samples. The six samples with false-negative results were all non-C. albicans by culture, and therefore, the results probably relate to the failure of the probe to hybridize to the amplicon. Conversely, 20 real-time PCR-positive samples (18 clinical CRC samples and 2 healthy control CRC samples) were detected among the 91 culture-negative CRC samples, possibly highlighting the higher sensitivity of real-time PCR (1 to 10 yeasts/ml) compared with that of CRC (>20 CFU/ml of concentrate). In addition, the PCR approach was not reliant on the presence of viable organisms, thereby further enhancing its relative sensitivity over culture. Fifteen of the 20 real-time PCR-positive, culture-negative samples were positive by at least one other PCR, and 8 culture-negative CRC samples were positive by all PCR methods. These findings accentuate the failure of culture to detect Candida in certain oral samples.
Both block-based PCRs produced more than double the number of culture-negative, PCR-positive results for CRC samples than real-time PCR, although the clinical significance of these results is uncertain. Dividing the culture-negative CRC samples into clinical and healthy control CRC samples reveals that the percentage of PCR-positive samples among the healthy control samples was much higher for the block-based PCRs (N18-specific PCR, 26%; ITS-specific PCR, 48%) than for the real-time PCR (6%). If culture is considered the gold standard, these findings could raise a question over the clinical relevance of block-based PCR-positive results for culture-negative samples.
As the number of N18-specific PCR-positive samples was greater than the number of culture-positive samples for both the healthy control and clinical populations but the 95% confidence intervals were approximately the same for both populations (2 to 26% for healthy controls, 4 to 24% for the clinical cases), the clinical significance of the additional N18-specific PCR-positive clinical samples is ambiguous. Conversely, as the real-time PCR detected Candida in only 6% of the culture-negative healthy control CRC samples (i.e., it did not produce large numbers of false-positive, clinically irrelevant results), the rise to a 30% rate of detection for the clinical (symptomatic) group is of interest. This is confirmed by the 95% confidence intervals, which determined that the number of healthy control samples positive by real-time PCR was not statistically different from the number of the healthy control samples positive by culture (95% confidence interval, 11 to 3%), whereas the number of additional clinical samples positive by real-time PCR was 2 to 15% greater (95% confidence intervals) than the number of clinical samples positive by culture, and as such, the results for the samples could be considered true positive.
The lower specificities of the block-based PCR methods over that of real-time PCR could, in part, account for the increased incidence of positive results by the block-based PCRs. Since our experiments with spiked samples confirmed the overall greater sensitivity of real-time PCR than other molecular methods, it was likely that specificity largely contributed to the increased numbers of block-based PCR-positive samples. However, different PCR conditions and template volumes may also have had an effect. Determination of whether the results for block-based PCR-positive, culture-negative CRC samples were true positive or false positive would require additional testing, such as sequencing or restriction fragment length polymorphism analysis (21, 22, 23), thus increasing the complexity, cost, and time required to obtain an assay result.
The question about the significance of culture-negative CRC samples and clinical relevance needs to be raised, particularly when positive results are evident by real-time PCR. It has been suggested that the presence of elevated numbers of Candida organisms indicates infection rather then normal commensal carriage (9). However, Candida levels up to 9 x 103 CFU/ml were evident in healthy controls in our studies, and on occasion, these levels were higher than those in patients with oral candidosis (data not shown). In patients with CHC, hyphal penetration of the oral mucosa occurs, and in these patients low numbers of yeasts may be recoverable from the mucosal surface (17). The value of culture in patients with CHC may therefore be limited, particularly if CRC is used for yeast isolation. Furthermore, when patients have received antifungal therapy the candidal load may be significantly reduced but not eradicated, partly explaining the high recurrence of oral candidosis among certain patients (19). In these circumstances the improved sensitivity of real-time PCR would be advantageous.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»